Alfredo Berruti

Professore Ordinario, Direttore Scuola Spec Oncologia, Università di Brescia. Direttore UO Oncologia Medica e Dipartimento Oncologico, ASST-Spedali Civili

[Alfredo Berruti @AlfredoBerruti]

https://t.co/oISINoIlUX

[Alfredo Berruti @AlfredoBerruti]

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prosta… https://t.co/LEktJHuzUa

[Alfredo Berruti @AlfredoBerruti]

MD Anderson Cancer Center hosted a successful ninth international congress on adrenal cancer. I would like to express my gratitude to the organizers, and in particular to Professor Mouhammed Habra. Thanks to the patient association Let's Cure for sharing testimonies.

[Alfredo Berruti @AlfredoBerruti]

Nasce a Brescia l’associazione “DALL’ALTRA PARTE” per mettere la persona al centro del percorso di cura https://t.co/8ZxQxrlK17

[Alfredo Berruti @AlfredoBerruti]

The adjuvant efficacy of bone resorption inhibitors in breast cancer patients is dependent on dose and schedule. Low drug exposure may be effective in preventing disease recurrence.
Adjuvant denosumab for early breast cancer–Evidence and controversy https://t.co/S7Sl4oCyqE

[Alfredo Berruti @AlfredoBerruti]

I'm grateful to HOLOGIC for this opportunity

[ESMO - Eur. Oncology @myESMO]

📣 New ESMO #ClinicalPracticeGuideline on Rare #EndocrineTumors: Evidence-based recommendations on imaging, diagnosis, treatment & follow-up of neuroendocrine, parathyroid and intrathyroid thymic neoplasms by experts across Europe. #RareTumors

🔗 https://t.co/c3lFb7icrX

[Alfredo Berruti @AlfredoBerruti]

And of course there is an interaction with lean mass
https://t.co/yfxU9WM3pN

[Alfredo Berruti @AlfredoBerruti]

The negative interaction between fat mass and bone health in estrogen deprived women is a new finding.

https://t.co/B2ijeg9dE4

[Alfredo Berruti @AlfredoBerruti]

Proud to be invited as a speaker at this prestigious congress at MD Anderson (Houston, TX).

[Alfredo Berruti @AlfredoBerruti]

Adverse Skeletal Related Events in Patients with Bone-Metastatic Pheochromocytoma/Paraganglioma - European Journal of Cancer https://t.co/Ch23jdtYJP

[Alfredo Berruti @AlfredoBerruti]

Meeturo's Italian paper tackles an important issue concerning the management of prostate cancer patients.

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management st… https://t.co/DpKFhdtumR

[Alfredo Berruti @AlfredoBerruti]

Changes in body composition in early breast cancer patients treated with aromatase inhibitors https://t.co/JEzKWjcPaO

[Alfredo Berruti @AlfredoBerruti]

The response of bone metastases to enzalutamide in prostate cancer patients enrolled in a prospective study was evaluated accurately by whole body diffusion weighted MRI in an Italian study coordinated by University of Brescia and ASST-Spedali Civili.

https://t.co/oaDAmtGjiI

[Alfredo Berruti @AlfredoBerruti]

Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma https://t.co/SI8X7Fzk5t

[ESMO - Eur. Oncology @myESMO]

New 📢 #MerkelCellCarcinoma: ESMO–@ERN_EURACAN Clinical Practice Guideline for diagnosis, treatment & follow-up. Algorithms also provided. MDT w/ high level of expertise should diagnose & make tx decisions. https://t.co/xC8bkdeIjo @ILugowska @PAscierto @rutkowskip1972 @AlfredoBerruti @ESMO_Open #ESMOGuidelines

[Alfredo Berruti @AlfredoBerruti]

Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer w… https://t.co/7DPjd0xvan

[Alfredo Berruti @AlfredoBerruti]

Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metast... https://t.co/WnXtrK3BJY

[Alfredo Berruti @AlfredoBerruti]

The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study https://t.co/1oTp2S8N3j

[Alfredo Berruti @AlfredoBerruti]

https://t.co/lA1Nzkty6Q